ROCHE HLDGS AG SPN ADR EACH REP 0.125GENUS (RHHBY)

29.47
0.15 0.51
OTC
Prev Close 29.62
Open 29.45
Day Low/High 29.32 / 29.49
52 Wk Low/High 25.25 / 33.77
Volume 1.58M
Exchange OTC
Shares Outstanding 5620.50B
Market Cap 177.38B
Div & Yield N.A. (N.A)

Latest News

FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review In Additional Type Of Advanced Bladder Cancer

FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review In Additional Type Of Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Roche Gains FDA Clearance For 18-Minute Anti-Mullerian Hormone Test To Assess Ovarian Reserve

Roche Gains FDA Clearance For 18-Minute Anti-Mullerian Hormone Test To Assess Ovarian Reserve

New blood test measures the remaining egg supply of women who are planning to become pregnant

FDA Approves Genentech's Lucentis® (Ranibizumab Injection) For Myopic Choroidal Neovascularization

FDA Approves Genentech's Lucentis® (Ranibizumab Injection) For Myopic Choroidal Neovascularization

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Genentech's Emicizumab For Hemophilia A Meets Primary Endpoint In Phase III Study

Genentech's Emicizumab For Hemophilia A Meets Primary Endpoint In Phase III Study

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary endpoint has been met for the Phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or...

Positive Phase III Results Of Genentech's Investigational Medicine OCREVUS™ (Ocrelizumab) Published In New England Journal Of Medicine

Positive Phase III Results Of Genentech's Investigational Medicine OCREVUS™ (Ocrelizumab) Published In New England Journal Of Medicine

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that data from three Phase III studies of its investigational medicine OCREVUS™ (ocrelizumab) - the OPERA I and OPERA II studies in...

FDA Extends Review Of Application For OCREVUS™ (Ocrelizumab)

FDA Extends Review Of Application For OCREVUS™ (Ocrelizumab)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Approves Genentech's Avastin® (Bevacizumab) Plus Chemotherapy For A Specific Type Of Advanced Ovarian Cancer

FDA Approves Genentech's Avastin® (Bevacizumab) Plus Chemotherapy For A Specific Type Of Advanced Ovarian Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Good Start Genetics Announces Marketing Agreement With Roche Diagnostics For Carrier Screening In The United States

Good Start Genetics Announces Marketing Agreement With Roche Diagnostics For Carrier Screening In The United States

Collaboration Marries Good Start's Proprietary Technology with Roche Diagnostics' Commercial Expertise for Broad Market Reach

Genentech's Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared To Rituxan

Genentech's Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared To Rituxan

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from the positive, pivotal Phase III GALLIUM study that compared Gazyva ® (obinutuzumab) plus chemotherapy followed by Gazyva...

Roche Launches DISCOVERY 5-Plex Procedure For Cancer Research Applications

Roche Launches DISCOVERY 5-Plex Procedure For Cancer Research Applications

Fully automated fluorescent multiplex procedure enables researchers to investigate up to five biomarkers on one tissue slide

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

In a few weeks, investors will know if Lilly's solanezumab is a groundbreaking treatment for Alzheimer's or another drug casualty to a disease that has eluded pharmaceutical companies for years.

Phase III GiACTA Study Shows Genentech's Actemra® Is Superior To Steroids Alone In Maintaining Steroid-Free Remission For People With Giant Cell Arteritis

Phase III GiACTA Study Shows Genentech's Actemra® Is Superior To Steroids Alone In Maintaining Steroid-Free Remission For People With Giant Cell Arteritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III GiACTA study, which evaluated Actemra ® (tocilizumab) in people with GCA.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.

European Drug Companies Get an Injection From Trump Victory

European Drug Companies Get an Injection From Trump Victory

The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.

Roche Launches New RNA HyperPrep Product Line

Roche Launches New RNA HyperPrep Product Line

A streamlined solution for the preparation of high-quality RNA-sequencing libraries

Alexion Soars, Then Falls Amid Takeover Rumors

Alexion Soars, Then Falls Amid Takeover Rumors

The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.

Genentech Showcases New Clinical Data Across A Variety Of Blood Diseases At American Society Of Hematology 2016 Annual Meeting

Genentech Showcases New Clinical Data Across A Variety Of Blood Diseases At American Society Of Hematology 2016 Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that more than 60 abstracts featuring nine of its approved or investigational medicines will be presented during the 58th American Society...

Roche's Haemophilia Drug Difficulties Has Rivals Looking for an Edge

Roche's Haemophilia Drug Difficulties Has Rivals Looking for an Edge

Pfizer, Bayer, Shire are among rivals bracing for Roche's ACE910.

Genentech To Present New Data On Medicines For Autoimmune Diseases And Severe Inflammatory Disorders At The 2016 ACR/ARHP Annual Meeting

Genentech To Present New Data On Medicines For Autoimmune Diseases And Severe Inflammatory Disorders At The 2016 ACR/ARHP Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from Actemra ® (tocilizumab) and Rituxan ® (rituximab) will be presented during the 2016 American College of...

Roche Announces FDA Approval For VENTANA PD-L1 (SP142) Assay To Support Immunotherapy Treatment Decisions In Lung Cancer

Roche Announces FDA Approval For VENTANA PD-L1 (SP142) Assay To Support Immunotherapy Treatment Decisions In Lung Cancer

First FDA-approved test to support patient treatment decisions for TECENTRIQ (atezolizumab) in non-small cell lung cancer

LabCorp Is First US Laboratory To Offer Molecular Testing With New Fully Automated Cobas 8800 System From Roche

LabCorp Is First US Laboratory To Offer Molecular Testing With New Fully Automated Cobas 8800 System From Roche

First high-throughput molecular platform approved for CLIA moderately complex testing expected to enhance quality, streamline workflow and better utilize staff

Roche Receives FDA Approval For Fully Automated Blood Screening Assay On The Cobas® 6800/8800 Systems

Roche Receives FDA Approval For Fully Automated Blood Screening Assay On The Cobas® 6800/8800 Systems

Next generation cobas® MPX assay now approved for donor screening applications in the United States

Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916

Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916

- Initiated SUNFISH study to evaluate RG7916 in Type 2/3 SMA patients -